BPTH - Bio-Path Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.00 (0.00%)
At close: 4:00PM EDT

18.19 +0.14 (0.78%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close18.05
Bid18.00 x 800
Ask18.19 x 800
Day's Range18.00 - 18.91
52 Week Range1.61 - 73.52
Avg. Volume3,991,908
Market Cap45.256M
Beta (3Y Monthly)2.72
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How This Highly Rated Biotech Stock Added To Its Meteoric Run
    Investor's Business Daily8 days ago

    How This Highly Rated Biotech Stock Added To Its Meteoric Run

    Bio-Path rocketed Monday after withdrawing its December offering for stocks and warrants. Bio-Path is working on a number of cancer treatments. Its lead program is in acute myeloid leukemia.

  • Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today
    InvestorPlace8 days ago

    Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today

    Bio-Path Holdings news about the company not offering additional shares of its stock has BPTH up on Monday.Source: Shutterstock Bio-Path Holdings (NASDAQ:BPTH) was planning to sell an additional 712,910 shares of BPTH stock to investors. It was pricing these shares at $25.95. However, the company's stock has been trading below that price recently. It closed on Friday at $15.65.If this new bit of Bio-Path Holdings news hadn't come about, the company would have been increasing its outstanding share amount by 28%. The company's total amount of outstanding shares was last recorded at 2.51 million as of March, 15, 2019, reports MarketWatch.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt's possible that the withdrawal of the BPTH stock offering is an attempt to increase the price of its shares. The goal may be to get shares of BPTH up above the offer price of $25.95 before moving forward again with plans to increase its outstanding shares, Seeking Alpha notes.BPTH stock was up 39% as of Monday morning and is up 311% since the start of the year. However, it's worth noting that Bio-Path Holdings saw a reverse stock split of 1 for 20 in late January. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? The stock also reached a peak of $73.52 on March 7 following positive data from a clinical trial. Despite this, it quickly fell back down to lower levels in the next couple of days. Even with this decline, it is was still sitting above its price prior to the data from the clinical trial. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today appeared first on InvestorPlace.

  • MarketWatch8 days ago

    Bio-Path's stock rockets after withdrawal of stock offering

    Bio-Path Holdings Inc.'s stock rocketed 48% in morning trade Monday, after the biotechnology company focused on cancer treatments filed to withdraw a common stock offering. Volume was 4.3 million shares, already more than half the full-day average of about 5.7 million shares. The company said in a filing late Friday that it submitted its request for withdrawal because it "elected to not pursue the sale of securities," and confirms that no securities were sold or will be sold. On March 12, the company said it had agreed with several institutional investors to sell 712,910 shares of common stock for $25.95 each. That would have represented a 28% increase to the 2.51 million shares outstanding as of March 15. On Jan. 18, the company effected a 1-for-20 reverse stock split. The stock has run up nearly 7-fold year to date (563%), while the iShares Nasdaq Biotechnology ETF has gained 14% and the S&P 500 has climbed 15.6%.

  • InvestorPlacelast month

    Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons

    With so much attention pointing once again to the again-escalating U.S.-China trade dispute, it's easy to overlook Bio-Path Holdings (NASDAQ:BPTH). However, the oncology specialist is easily one of the best-performing investments of 2019. Year-to-date, BPTH stock has gained a mind-blowing near-500%.More importantly, a fundamental catalyst supports the dramatic rise in valuation. A favorable clinical trial of the company's acute myeloid leukemia drug lifted Bio-Path stock from the doldrums. This news has obvious positive implications, as this particular cancer has a market size of $701.6 million. Overall, leukemia's market value will likely hit $12 billion in a few years.At the same time, biotechnology firms are hardly stable investments. While BPTH stock currently enjoys the afterglow of a promising trial, it could just as easily go awry. After all, if cancer research was straightforward, we'd already have a cure.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvariably, though, the skyrocketing Bio-Path stock commands our attention. Should you buy into this winning streak, or is this hand destined to cool? Here are three pros and three cons to consider: Pro 1: A Possible Breakthrough Could Further Boost BPTH StockI'm not breaking new ground when I say that cancer is an uncomfortable subject. However, acute myeloid leukemia is a nasty strain. The disease spreads very rapidly if left untreated. By entering the bloodstream, this cancer can affect the liver, spleen, central nervous system, and testicles. * Top 7 Service Sector Stocks That Will Pay You to Own Them The latter may have caught the attention of Wall Street's men, who fueled the spike in BPTH stock.In all seriousness, though, the latest clinical trial offered encouraging data. Out of 17 patients in the study, 11 responded to Bio-Path's prexigebersen drug. And of those 11, five experienced a complete response. Pro 2: Bio-Path Stock Levers Profound TechnologiesA thousand years from now, I'm sure that our future progeny will look back on us with macabre fascination for how we treated cancer by blasting patients with radiation. I can't help but bring up the obvious question: doesn't radiation cause cancer?Fortunately, much smarter people than I have answered this inquiry. Bio-Path's solution is their proprietary DNAbilize platform. In short, this enables oncologists to precisely deliver cancer-killing therapies to affected cells without nuking the patient.Such technologies lever a broader impact on this industry. Some patients simply don't have the physical strength to endure chemotherapy or radiology. DNAbilize is a lifesaver on multiple fronts, further bolstering the case for Bio-Path stock. Pro 3: BPTH Probably Already Hit Rock-BottomI'm not always comfortable with the argument that a particular stock has priced in all the bad news. Unless you're privy to insider information -- at which point you shouldn't act on that info -- you just don't know if more nasty stuff lies ahead.However, I can't imagine BPTH stock falling even more than it already has. Bear in mind that shares used to trade for well over $500 just a few years ago. With that context, BPTH appears like a bargain, even with this year's mooning. Con 1: Shares Used to Trade at $500-plusOn one hand, the ability to buy Bio-Path stock for pennies on the dollar appeals to many contrarians. But those with a critical eye will argue that a reason exists for the meltdown.Let's look even further back. In early January 2014, BPTH stock was on the cusp of clearing $1,000. In May of 2008, and just prior to the Great Recession, it hit four digits.The argument that "it can't get any worse" failed these early investors "bigly." You don't want to repeat their mistake. Con 2: Bio-Path has Tough CompetitionWhile Bio-Path's DNAbilize platform appears profoundly impressive, it's not the only party in town. BPTH is riding the broader category of gene therapy, or the targeted delivery of disease-fighting therapies. But other names, including CRISPR Therapeutics (NASDAQ:CRSP), Roche Holding (OTCMKTS:RHHBY), and Editas Medicine (NASDAQ:EDIT) compete aggressively in this sector. * 5 Cloud Stocks to Help Your Portfolio Fly Given the historical volatility in BPTH stock, I want some reassuring factors that I can depend on. Unfortunately, Bio-Path doesn't have a moat, which makes me jittery about its sudden rise. Con 3: Biotech is Incredibly VolatileRight now, everyone has mad love for Bio-Path stock because of its unexpected ascent. However, I've seen this story play out before in this wild market segment. All it takes is one bad trial to undo years of effort and research.Plus, BPTH stock has two obstacles regarding its drug pipeline. Management must demonstrate that their therapies can consistently beat placebo, which is no easy task. Plus, they have to show that their solutions are superior to the competition. Again, that's no gimme. Bottom Line on BPTH StockAdmittedly, I see the both the technical and fundamental potential for BPTH, and I'm personally intrigued. However, I keep going back to the inherent volatility of the biotech industry and Bio-Path stock. Yes, it enjoyed a positive paradigm-shift, but it could just as easily go sour.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons appeared first on InvestorPlace.

  • Benzinga2 months ago

    The Secret To Trading Stocks Like Bio-Path That Helped Me Quit My Desk Job And Make Thousands

    That’s quite a headline, but let me ward off anyone looking for a get rich quick scheme or skeptics who hate-clicked this article. I made $8,500 on Bio-Path Holdings, Inc. (NASDAQ: BPTH ) over the course ...

  • MarketWatch2 months ago

    UPDATE: Bio-Path stock gains another 130% on Thursday

    Shares of Bio-Path Holdings Inc. shot up another 130% on Thursday morning, one day after the company announced an update to its Phase 2 trial data on prexigebersen, a potential therapy for patients with acute myeloid leukemia (AML). The tiny biotech was the most heavily traded stock on the Nasdaq on Wednesday afternoon, with shares rocketing 160%. The trial enrolled 17 patients and looked at the safety and efficacy of prexigebersen combined with low-dose cytarabine compared with just low-dose cytarabine alone. Low-dose cytarabine is currently standard of care for patients who can't or do not want to be treated with more intensive chemotherapy. The company said the latest results showed that the rate of patients achieving complete remission (including those with incomplete platelet recovery and those with incomplete hematologic recovery) was 29%. The rate of complete remission for low-dose cytarabine alone is 7-13%, the company said. Bio-Path had already released positive trial results last year, and Wednesday's results were an update to that trial data. The company also noted that 68% of the patients were secondary acute myeloid leukemia patients, a particularly difficult class to treat, something not disclosed previously. Bio-Path added that it saw an opportunity for its drug BP1002 based on the recent FDA approval of venetoclax as a combination treatment for patients with AML and chronic lymphocytic leukemia. Venetoclax was developed and marketed by AbbVie and Roche Holding Ltd subsidiary Genentech. BP1002 targets the same protein as venetoclax but via a different pathway. Bio-Path thinks BP1002 could provide an alternative for patients who have relapsed while on venetoclax. Shares of Bio-Path have gained 379% in the past three months, while the S&P 500 has gained 4.4%.

  • Is Bio-Path Holdings, Inc.’s (NASDAQ:BPTH) CEO Pay Justified?
    Simply Wall St.2 months ago

    Is Bio-Path Holdings, Inc.’s (NASDAQ:BPTH) CEO Pay Justified?

    Peter Nielsen became the CEO of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similarRead More...

  • Benzinga3 months ago

    The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...

  • Could Bio-Path Holdings, Inc.’s (NASDAQ:BPTH) Investor Composition Influence The Stock Price?
    Simply Wall St.4 months ago

    Could Bio-Path Holdings, Inc.’s (NASDAQ:BPTH) Investor Composition Influence The Stock Price?

    Every investor in Bio-Path Holdings, Inc. (NASDAQ:BPTH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • Benzinga5 months ago

    The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

    Notwithstanding the scanty news flow, biotech stocks came under intense selling pressure last week, pushing the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) further into the red. Here's a list of ...

  • Associated Press5 months ago

    Bio-Path: 3Q Earnings Snapshot

    On a per-share basis, the Bellaire, Texas-based company said it had a loss of 27 cents. The company's shares closed at 44 cents. A year ago, they were trading at $2.97. _____ This story was generated by ...

  • Simply Wall St.6 months ago

    What does Bio-Path Holdings Inc’s (NASDAQ:BPTH) Balance Sheet Tell Us About Its Future?

    The direct benefit for Bio-Path Holdings Inc (NASDAQ:BPTH), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...

  • Associated Press8 months ago

    Bio-Path: 2Q Earnings Snapshot

    The Bellaire, Texas-based company said it had a loss of 15 cents per share. The company's shares closed at $1.41. A year ago, they were trading at $3. _____ This story was generated by Automated Insights ...

  • With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?
    Simply Wall St.11 months ago

    With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...